Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | PTPRB | P23467 | 1/20 | 0.53 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.53 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.51 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511955 | 1.00 | MAOB (0.70) | MAOBHRH3PTPN1PTPRCPTPN2 | |
| SCHEMBL13279971 | 0.84 | MAOB (0.73) | MAOBHRH3PTPN1PTPRCPTPN2 | |
| SCHEMBL4883457 | 0.84 | MAOB (0.72) | MAOBPTPN1PTPRCPTPN2PTPRB | |
| SCHEMBL1451649 | 0.83 | MAPK14 (0.48) | MAOBIDO1 | |
| SCHEMBL676931 | 0.82 | TAAR1 (0.54) | MAOBIDO1 | |
| SCHEMBL5512565 | 0.82 | MAOB (0.59) | MAOBPTPN1PTPN2PTPRBPTPN6 | |
| SCHEMBL23266730 | 0.82 | MAOB (0.70) | MAOBPTPN1PTPRCPTPN2PTPRB | |
| SCHEMBL508697 | 0.82 | MAOB (0.70) | MAOBHRH3PTPN1PTPRCPTPN2 | |
| SCHEMBL21568941 | 0.82 | MAOB (0.70) | MAOBPTPN1PTPRCPTPN2PTPRB | |
| SCHEMBL4339843 | 0.82 | MAOB (1.00) | MAOBPTPN1PTPRCPTPN2PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528901-B9 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-2528901-B1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-8791272-B2 | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2528901-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092140-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH3 | MAOB 2197/4885HRH3 3/4885PTPN1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.